Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Dermata Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- +6 vs. Q1 2026
- Shares held
- 122.5K
- +16.0K (+15.0%) vs. Q1 2026
- Total value
- $158.0K
- +$29.2K (+22.7%) vs. Q1 2026
- New holders
- 7
- 1 more added
- Sold out
- 1
- 2 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DRMA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $158.0K |
| Q1 2026 | 7 | $128.9K |
| Q4 2025 | 7 | $62.4K |
| Q3 2025 | 5 | $463.0K |
| Q2 2025 | 10 | $297.5K |
| Q1 2025 | 8 | $561.2K |
| Q4 2024 | 6 | $61.5K |
| Q3 2024 | 4 | $10.6K |
| Q2 2024 | 6 | $78.3K |
| Q1 2024 | 7 | $29.8K |
| Q4 2023 | 6 | $184.8K |
| Q3 2023 | 6 | $110.1K |
| Q2 2023 | 8 | $236.3K |
| Q1 2023 | 4 | $47.4K |
| Q4 2022 | 11 | $118.8K |
| Q3 2022 | 9 | $101.0K |
| Q2 2022 | 11 | $554.0K |
| Q1 2022 | 8 | $91.0K |
| Q4 2021 | 11 | $226.0K |
| Q3 2021 | 8 | $1.19M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Dermata Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 2 | $3 | 0.00% | +2 | New |
| Highline Wealth Partners LLC | 26 | $34 | 0.00% | +26 | New |
| SBI Securities Co., Ltd. | 101 | $130 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 270 | $348 | 0.00% | +270 | New |
| MCF Advisors LLC | 1,732 | $2.23K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,860 | $4.98K | 0.00% | +3,144+439.1% | Added |
| Advisory Alpha, LLC | 10,000 | $12.9K | 0.00% | +10,000 | New |
| XTX Topco Ltd | 14,787 | $19.1K | 0.00% | +14,787 | New |
| Susquehanna International Group, LLP | 15,989 | $20.6K | 0.00% | +15,989 | New |
| UBS Group AG | 16,796 | $21.7K | 0.00% | −18,812−52.8% | Reduced |
| State Street Corp | 18,747 | $24.2K | 0.00% | +18,747 | New |
| Welch & Forbes LLC | 20,000 | $25.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 20,203 | $26.1K | 0.00% | −28,131−58.2% | Reduced |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |